SCHEMBL3346307

SCHEMBL3346307

O=C1CN(C(=O)Nc2ccccc2)C(=O)N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
ALDH1A1 P00352 2/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.49
TP53 P04637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
PKM P14618 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.47
KDM4E B2RXH2 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10665204 0.74 GAA (0.51) KMT2AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL11768769 0.74 TSHR (0.48) KMT2AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL31140232 0.74 HTT (0.69) KMT2AALDH1A1MAPTSMN1; SMN2RAB9A
SCHEMBL11728162 0.73 POLB (0.55) ALDH1A1GAAMAPTSMN1; SMN2TP53
SCHEMBL345503 0.72 CRBN (0.38) KMT2AALDH1A1MAPTSMN1; SMN2PKM
SCHEMBL31126366 0.71 POLB (0.53) ALDH1A1GAAMAPTSMN1; SMN2TP53
SCHEMBL11647947 0.70 CYP2C9 (0.57) ALDH1A1GAAMAPTSMN1; SMN2TP53
SCHEMBL27552925 0.70 HTT (0.59) KMT2AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL14413877 0.70 ALDH1A1 (1.00) ALDH1A1GAAMAPTSMN1; SMN2TP53
SCHEMBL27338294 0.69 SMN1; SMN2 (0.55) KMT2AALDH1A1GAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144885-B1 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2016-06-29 EP disclosed
US-8735437-B2 Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2014-05-27 US disclosed
US-20100105719-A1 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2144885-A1 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS Sanofi-Aventis (FR) 2010-01-20 EP disclosed
WO-2008122352-A1 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI-AVENTIS (FR) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105719-A1 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS PNLIP, PLD1, PLD2 KMT2A 1644/4885ALDH1A1 577/4885GAA 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.